| Bioactivity | Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria,et al[1][2]. | ||||||||||||
| In Vivo | In toxicology study in animals, Pidotimod (oral gavage; 800 mg/kg;12 months) is non-toxic in rats and is non-toxic dogs at 600 mg/kg. Pidotimod is non-teratogenic in rats (600 mg/kg orally or 1000 mg/kg IV) and has no effects on subsequent embryofoetal development in rats (up to 1000 mg/kg/day),it has no perinatal or postnatal toxic effects in rats (600 mg/kg orally)[1].In ex vivo experiments in mice, Pidotimod (intraperitoneal administration; 200 mg/kg; 5 days) potentiats natural killer (NK) cell activity and produces an increase in the proliferative response to mitogens such as concanavalin A (ConA) and interleukin-2 (IL-2)[2]. Pidotimod (intraperitoneal administration; 10-100 mg/kg) normalizes depletion of peritoneal macrophage numbers, and significantly increases macrophage superoxide anion (O2–) production in methylprednisolone-induced immunosuppressed mice[2]. | ||||||||||||
| Name | Pidotimod | ||||||||||||
| CAS | 121808-62-6 | ||||||||||||
| Formula | C9H12N2O4S | ||||||||||||
| Molar Mass | 244.27 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Ashok Mahashur, et al. Pidotimod: In-depth review of current evidence. Lung India [2]. Ning Zhao, et al. Pidotimod: a review of its pharmacological features and clinical effectiveness in respiratory tract infections. Expert Rev Anti Infect Ther. 2019 Oct;17(10):803-818. |